A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

Not specified

Study Completion Date

March 31, 2001

Conditions
HIV Infections
Interventions
DRUG

Aldesleukin

Trial Locations (14)

10016

NYU Med. Ctr., Dept. of Medicine, New York

10032

Columbia IMPAACT CRS, New York

Incarnation Children's Ctr., New York

23219

VCU Health Systems, Dept. of Peds, Richmond

32209

Univ. of Florida Jacksonville NICHD CRS, Jacksonville

77030

Texas Children's Hosp. CRS, Houston

90801

Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach

191044318

The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia

606143394

Chicago Children's CRS, Chicago

606371470

Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago

701122699

Tulane/LSU Maternal/Child CRS, New Orleans

802181088

Univ. of Colorado Denver NICHD CRS, Aurora

941430105

UCSF Pediatric AIDS CRS, San Francisco

021155724

HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000849 - A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children | Biotech Hunter | Biotech Hunter